Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
Yan Xie, Benjamin Bowe, Andrew K. Gibson, et al.
JAMA Internal Medicine (2021) Vol. 181, Iss. 8, pp. 1043-1043
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Long COVID after breakthrough SARS-CoV-2 infection
Ziyad Al‐Aly, Benjamin Bowe, Yan Xie
Nature Medicine (2022) Vol. 28, Iss. 7, pp. 1461-1467
Open Access | Times Cited: 687
Risks and burdens of incident diabetes in long COVID: a cohort study
Yan Xie, Ziyad Al‐Aly
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 5, pp. 311-321
Open Access | Times Cited: 468
Risks of mental health outcomes in people with covid-19: cohort study
Yan Xie, Evan Xu, Ziyad Al‐Aly
BMJ (2022), pp. e068993-e068993
Open Access | Times Cited: 358
Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status
Yan Xie, Benjamin Bowe, Ziyad Al‐Aly
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 278
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
Rodica Pop‐Busui, James L. Januzzi, Dennis Bruemmer, et al.
Diabetes Care (2022) Vol. 45, Iss. 7, pp. 1670-1690
Open Access | Times Cited: 231
Kidney Outcomes in Long COVID
Benjamin Bowe, Yan Xie, Evan Xu, et al.
Journal of the American Society of Nephrology (2021) Vol. 32, Iss. 11, pp. 2851-2862
Open Access | Times Cited: 176
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
Alison K. Wright, Matthew Carr, Evangelos Kontopantelis, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 909-918
Open Access | Times Cited: 96
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs
Dhruv Mahtta, David J. Ramsey, Michelle Lee, et al.
Diabetes Care (2022) Vol. 45, Iss. 2, pp. 372-380
Open Access | Times Cited: 89
Risks and burdens of incident dyslipidaemia in long COVID: a cohort study
Evan Xu, Yan Xie, Ziyad Al‐Aly
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 2, pp. 120-128
Open Access | Times Cited: 84
Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How?
Edouard L. Fu
Journal of the American Society of Nephrology (2023) Vol. 34, Iss. 8, pp. 1305-1314
Open Access | Times Cited: 49
Mapping the effectiveness and risks of GLP-1 receptor agonists
Yan Xie, Taeyoung Choi, Ziyad Al‐Aly
Nature Medicine (2025)
Closed Access | Times Cited: 15
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Yan Xie, Benjamin Bowe, Hong Xian, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 11, Iss. 9, pp. 644-656
Closed Access | Times Cited: 40
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin
HoJin Shin, Sebastian Schneeweiß, Robert J. Glynn, et al.
Annals of Internal Medicine (2022) Vol. 175, Iss. 7, pp. 927-937
Closed Access | Times Cited: 34
A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults
Yuan‐Di C. Halvorsen, John Paul Lock, Juan P. Frías, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 293-301
Open Access | Times Cited: 21
Comparative Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis
Ghadeer K. Dawwas, James Flory, Sean Hennessy, et al.
Diabetes Care (2022) Vol. 45, Iss. 4, pp. 919-927
Open Access | Times Cited: 20
Inhibiteurs du cotransporteur sodium-glucose de type 2 (iSGLT2) : bénéfices cardiovasculaires et rénaux au-delà du contrôle glycémique
Maïmouna Ndour Mbaye, Jean-Baptiste Anzouan-Kacou, Weu Mélanie Tia, et al.
Médecine des Maladies Métaboliques (2025)
Closed Access
mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy
Sumit Saha, Xianjun Fang, Christopher D. Green, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15078-15078
Open Access | Times Cited: 10
Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK
Antonio González‐Pérez, David Vizcaya, María Eugenia Sáez, et al.
BMJ Open Diabetes Research & Care (2023) Vol. 11, Iss. 1, pp. e003072-e003072
Open Access | Times Cited: 6
Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes
Rohit Vashisht, Ayan R. Patel, Lisa Dahm, et al.
JAMA Network Open (2023) Vol. 6, Iss. 10, pp. e2336613-e2336613
Open Access | Times Cited: 6
Long Covid after Breakthrough COVID-19: the post-acute sequelae of breakthrough COVID-19
Ziyad Al‐Aly, Benjamin Bowe, Yan Xie
Research Square (Research Square) (2021)
Open Access | Times Cited: 14
New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals
Mark A. Jarosinski, Yen‐Shan Chen, Nicolás Varas, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 4, pp. 909-928
Open Access | Times Cited: 14
One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus
Rajmohan Seetharaman, Sudhir Pawar, Manjari Advani
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 4, pp. 1598-1612
Open Access | Times Cited: 11
Therapeutic Applications of Plant and Nutraceutical-Based Compounds for the Management of Type 2 Diabetes Mellitus: A Narrative Review
Susha Dinesh, Sameer Sharma, Rajan Chourasiya
Current Diabetes Reviews (2023) Vol. 20, Iss. 2
Closed Access | Times Cited: 4
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure
Koshiro Kanaoka, Yoshitaka Iwanaga, Michikazu Nakai, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 9, Iss. 5, pp. 444-452
Closed Access | Times Cited: 4
Profiles of sulfonylurea use in Diabetes Mellitus type 2: an analysis of clinical practice over the last 10 years
Fabio Baccetti, Cristiano Crisafulli, Francesco Andreozzi, et al.
Diabetes Research and Clinical Practice (2024) Vol. 214, pp. 111781-111781
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top